{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:02:39Z","timestamp":1788321759978,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.seizure.2013.03.016","type":"journal-article","created":{"date-parts":[[2013,4,25]],"date-time":"2013-04-25T21:32:34Z","timestamp":1366925554000},"page":"528-536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine"],"prefix":"10.1016","volume":"22","author":[{"given":"Gaetano","family":"Zaccara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Giovannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Maratea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Fadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Verrotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.seizure.2013.03.016_bib0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF02230884","article-title":"Antiepileptic drug toxicity: definition and mechanism of action","volume":"7","author":"Beghi","year":"1986","journal-title":"Italian Journal of Neurological Sciences"},{"issue":"7","key":"10.1016\/j.seizure.2013.03.016_bib0010","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2165\/11630700-000000000-00000","article-title":"Safety and tolerability of antiepileptic drug treatment in children with epilepsy","volume":"35","author":"Guerrini","year":"2012","journal-title":"Drug Safety"},{"key":"10.1016\/j.seizure.2013.03.016_bib0015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1684\/j.1950-6945.2004.tb00064.x","article-title":"Adverse motor effects induced by antiepileptic drugs","volume":"6","author":"Zaccara","year":"2004","journal-title":"Epileptic Disorders"},{"issue":"1","key":"10.1016\/j.seizure.2013.03.016_bib0020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0025-6196(11)60965-8","article-title":"Second-generation antiepileptic drugs\u2019 impact on balance: a meta-analysis","volume":"82","author":"Sirven","year":"2007","journal-title":"Mayo Clinic Proceedings"},{"issue":"July","key":"10.1016\/j.seizure.2013.03.016_bib0025","article-title":"The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials","author":"Zaccara","year":"2012","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2013.03.016_bib0030","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.yebeh.2011.07.035","article-title":"Adjunctive lacosamide in clinical practice: sodium blockade with a difference?","volume":"22","author":"Stephen","year":"2011","journal-title":"Epilepsy Behavior"},{"key":"10.1016\/j.seizure.2013.03.016_bib0035","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archneur.1997.00550160063017","article-title":"Cerebellar atrophy decreases the threshold of carbamazepine toxicity in patients with chronic focal epilepsy","volume":"54","author":"Specht","year":"1997","journal-title":"Archives of Neurology"},{"issue":"4","key":"10.1016\/j.seizure.2013.03.016_bib0040","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1528-1167.2010.02966.x","article-title":"The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Zaccara","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2013.03.016_bib0045","unstructured":"Medicines and Healthcare products Regulatory Agency. Oxcarbazepine tablets: summary of product characteristics [online]. http:\/\/www.mhra.gov.uk\/home\/groups\/par\/documents\/websiteresources\/con052082.pdf [accessed 03.09.2012]."},{"key":"10.1016\/j.seizure.2013.03.016_bib0050","unstructured":"Food and Drug Administration. Trileptal\u00ae (oxcarbazepine tablets). US prescribing information [online]. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021014s015s019s022s024s025s027s028,021285s009s013s015s018s019s020s022lbl.pdf [accessed 03.09.2012]."},{"key":"10.1016\/j.seizure.2013.03.016_bib0055","unstructured":"European Medicines Agency. Zebinix\u00ae (eslicarbazepine acetate tablets): summary of product characteristics [online]. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000988\/WC500047225.pdf [accessed 03.09.2012]."},{"key":"10.1016\/j.seizure.2013.03.016_bib0060","unstructured":"European Medicines Agency. Vimpat\u00ae (lacosamide tablets): summary of product characteristics [online]. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000863\/WC500050338.pdf [accessed 03.09.2012]."},{"key":"10.1016\/j.seizure.2013.03.016_bib0065","unstructured":"Food and Drug Administration. Vimpat\u00ae (lacosamide tablets). US prescribing information [online]. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022255lbl.pdf [accessed 03.09.2012]."},{"issue":"July 1","key":"10.1016\/j.seizure.2013.03.016_bib0070","first-page":"CD005612","article-title":"Pregabalin add-on for drug-resistant partial epilepsy","author":"Lozsadi","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.seizure.2013.03.016_bib0075","series-title":"Review manager (RevMan) [Computer program]. Version 5.1. The Nordic Cochrane Centre","author":"RevMan","year":"2011"},{"key":"10.1016\/j.seizure.2013.03.016_bib0080","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1016\/j.seizure.2013.03.016_bib0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d1555","article-title":"Network meta-analysis. Results can be summarised in a simple figure","volume":"342","author":"Fadda","year":"2011","journal-title":"British Medical Journal"},{"issue":"2\u20133","key":"10.1016\/j.seizure.2013.03.016_bib0090","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eplepsyres.2010.01.014","article-title":"Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy","volume":"89","author":"Ben-Menachem","year":"2010","journal-title":"Epilepsy Research"},{"issue":"3","key":"10.1016\/j.seizure.2013.03.016_bib0095","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1528-1167.2007.00984.x","article-title":"Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures","volume":"48","author":"Elger","year":"2007","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2013.03.016_bib0100","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"BIA-2093-301 investigators study group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.seizure.2013.03.016_bib0105","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0404.2009.01218.x","article-title":"BIA-2093-303 investigators study group. Efficacy and safety of 800 and 1200mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures","volume":"120","author":"Gil-Nagel","year":"2009","journal-title":"Acta Neurologica Scandinavica"},{"issue":"7","key":"10.1016\/j.seizure.2013.03.016_bib0110","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2013.03.016_bib0115","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":"SP754 study group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial","volume":"51","author":"Chung","year":"2010","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2013.03.016_bib0120","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":"SP755 study group. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial","volume":"50","author":"Hal\u00e1sz","year":"2009","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.seizure.2013.03.016_bib0125","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/j.1499-1654.2000.001597.x","article-title":"Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy","volume":"41","author":"Barcs","year":"2000","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.seizure.2013.03.016_bib0130","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/j.1528-1167.2011.03047.x","article-title":"Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis","volume":"52","author":"Costa","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2013.03.016_bib0135","article-title":"Clinical efficacy and safety of the newer antiepileptic drugs as adjunctive treatment in adults with refractory partial-onset epilepsy: a meta-analysis of randomized placebo-controlled trials","author":"Gao","year":"2012","journal-title":"Epilepsy Research"},{"issue":"9","key":"10.1016\/j.seizure.2013.03.016_bib0140","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.seizure.2012.07.011","article-title":"The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: a systematic review and indirect comparison","volume":"21","author":"Martyn-St James","year":"2012","journal-title":"Seizure"},{"issue":"July","key":"10.1016\/j.seizure.2013.03.016_bib0145","article-title":"Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers","author":"Nunes","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2013.03.016_bib0150","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/mol.107.039867","article-title":"The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels","volume":"73","author":"Errington","year":"2008","journal-title":"Molecular Pharmacology"},{"issue":"14","key":"10.1016\/j.seizure.2013.03.016_bib0155","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/jm980627g","article-title":"Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5Hdibenz[b,f]azepine-5-carboxamide derivatives","volume":"42","author":"Benes","year":"1999","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.seizure.2013.03.016_bib0160","first-page":"103","article-title":"Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures","volume":"6","author":"Brown","year":"2010","journal-title":"Therapeutics and Clinical Risk Management"},{"issue":"1","key":"10.1016\/j.seizure.2013.03.016_bib0165","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2125.2007.02984.x","article-title":"Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent carbamazepine tablets","volume":"65","author":"Tothfalusi","year":"2008","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1016\/j.seizure.2013.03.016_bib0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1600-0404.1990.tb01579.x","article-title":"Conventional vs controlled-release carbamazepine: a multicentre, double-blind, cross-over study","volume":"82","author":"Canger","year":"1990","journal-title":"Acta Neurologica Scandinavica"},{"issue":"2","key":"10.1016\/j.seizure.2013.03.016_bib0175","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.eplepsyres.2006.01.011","article-title":"Relationship between serum mono-hydroxy-carbazepine concentrations and adverse effects in patients with epilepsy on high-dose oxcarbazepine therapy","volume":"69","author":"Striano","year":"2006","journal-title":"Epilepsy Research"},{"issue":"1\/2","key":"10.1016\/j.seizure.2013.03.016_bib0180","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.eplepsyres.2011.05.013","article-title":"Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures","volume":"96","author":"Perucca","year":"2011","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.seizure.2013.03.016_bib0185","series-title":"The treatment of epilepsy","first-page":"451","article-title":"Oxcarbazepine","author":"Faught","year":"2005"},{"issue":"2","key":"10.1016\/j.seizure.2013.03.016_bib0190","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1528-1167.2010.02915.x","article-title":"Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis","volume":"52","author":"Rheims","year":"2011","journal-title":"Epilepsia"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131113000976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131113000976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:42:46Z","timestamp":1761010966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131113000976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1059131113000976"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2013.03.016","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2013.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}